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Abstract
Background: Endothelin-1 (ET-1) is involved in pulmonary vascular remodeling. The aim of this study was to
investigate the biochemical interactions between PPAR-γ, TGF-β1 and ET-1 in vitro.
Methods: A549 cells were pre-treated with S2505 (10 μM), S2871 (10 μM) with/without SB203580 (10 μM) for 60 min
following 2 h treatment with 10 ng/mL TGF-β1. A549 cells were also transfected with positive or negative PPAR-γ
plasmids for comparison. RT-PCR, ELISA, western blotting and confocal laser scanning microscopy (CLSM) were used to
measure the relevant expression of mRNA, protein, mediators of pathways and nuclear factor translocation.
Results: SB203580 inhibited TGF-β1 induced ET-1 expression in A549 cells. S2871 decreased PPAR-γ mRNA and
increase TGF-β1-induced ET-1 expression. S2871 increased phosphorylation of p38 MAPK and Smad2. Cells transfected
with PPAR-γ negative plasmid increased TGF-β1 induced ET-1 expression, and increased the expression of
phospho-p38 MAPK and phospho-Smad2. S2505 increased PPAR-γ mRNA expression, suppressed the increased
TGF-β1-induced expression of ET-1. S2505 inhibited TGF-β1 induced phosphorylation of p38 MAPK and Smad2, also
the nuclear translocation of Smad2. Cells transfected with PPAR-γ positive plasmid reduced TGF-β1-induced ET-1
expression, and inhibited the expression of phospho-p38 MAPK and phospho-Smad2.
Conclusions: TGF-β1 induced release of endothelin-1 is PPAR-γ dependent in cultured A549 cells.
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Background
Pulmonary arterial hypertension (PAH) is a life-
threatening illness characterized by increased pulmonary
vascular resistance (PVR) following right heart dysfunc-
tion [1]. Several changes in the diagnosis and manage-
ment of this disease have been implemented by the
National Institute of Health (NIH) registry since the
1980s [2], but the outcome of this fatal disease although
improved still remains poor [3, 4]. Recent research
revealed that the median survival of PAH was between 3
and 5 years [5, 6].
The pathogenesis of PAH still remains elusive and
there is general agreement that the endothelial dysfunc-
tion and pulmonary vascular remodeling appear to be
the key prerequisite reasons for the initiation of the dis-
ease. Any stimuli leading to vascular endothelial injury,
vasoconstriction, cell proliferation, proinflammatory,
thrombogenic functions and vascular remodeling are
likely to contribute to PAH [7, 8]. The increase in PVR
is progressive and finally leads to right heart failure and
death. Many factors may be involved in this progressive
process and an understanding of molecular mechanisms
of PAH has given rise to numerous lines of research and
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important discoveries in the last decade. The presence of
inflammatory cytokines and increased expression of
growth and transcriptional factors are thought to con-
tribute directly to further recruitment of inflammatory
cells and proliferation of smooth muscle and endothelial
cells resulting in increased PVR [9]. ET-1, prostacyclin,
TGF-β family and nitric oxide (NO) are closely related
to pulmonary arterial smooth muscle cell (PASMC) pro-
liferation [10].
ET-1 is a 21-AA peptide which regulates vasoconstric-
tion and proliferative responses in numerous cell types
and recent findings have re-established the role of ET-1
in the pulmonary vascular remodeling process. ET-1
plasma levels are prominently increased in PAH patients
and correlate with PVR and PAH [10–13]. The concen-
tration of ET-1 in pulmonary circulation correlated with
the increased levels of PVR, as well as the severity of the
structural abnormalities found in distal pulmonary arter-
ies as measured by intravascular ultrasound [14]. Factors
that can affect the expression of ET-1 will also affect
pulmonary vascular remodeling. TGF-β1 is one of the
multifunctional peptides that regulate proliferation, dif-
ferentiation and other functions in several cell types. In-
creased expression of TGF-β1 has been observed in
PAH vessel and contribute to PASMC growth and colla-
gen deposition [15]. The effects of ET-1 leading to pul-
monary vascular remodeling are enhanced by the
presence of TGF-β1 in human PASMC [16]. The patho-
physiology of pulmonary hypertension differs according
to the presence or absence of lung disease. Idiopathic
pulmonary fibrosis (IPF) is associated with a high inci-
dence of pulmonary hypertension [17, 18]. Epithelial to
mesenchymal transformation (EMT) of alveolar epithe-
lial cells has been recognized as a potential contributor
to IPF and TGF-β1 has a close relationship with EMT in
A549 cells [19, 20]. Previous studies suggested that
TGF-β1-induced A549 cells undergo EMT via phosphor-
ylation of Smad2 [21, 22] and peroxisome proliferator-
activated receptor gamma (PPAR-γ) ligands inhibited
profibrotic changes in TGF-β1-stimulated cells [23, 24].
PPAR-γ is a ligand-activated nuclear receptor which reg-
ulates the transcription of genes involved in adipogene-
sis, insulin sensitization, inflammation, as well as
vascular remodeling [25, 26]. Early research suggested
that PPAR-γ activators inhibited oxidized low-density
lipoprotein-induced induced ET-1 production in endo-
thelial cells [27]. The expression of PPAR-γ was reduced
in the pulmonary tissue of rat models of this disease [28]
and pharmacological activation of PPAR-γ could effect-
ively attenuate the upregulation of ET-1 signaling in
mice or human pulmonary artery endothelial cells [29].
The way in which TGF-β1 and PPAR-γ regulate the
expression of ET-1 and what signaling pathways partici-
pate in this process remain unclear. We hypothesize that
TGF-β1 can stimulate A549 cells to produce ET-1 and
that while PPAR-γ may has some effects on this pro-
gress. We measured the effects of TGF-β1 and PPAR-γ
on ET-1 expression and production in A549 cells by
using RT-PCR, ELISA, western blot and confocal laser
scanning microscopy (CLSM).
Methods
Cell culture
Human type II alveolar epithelial cell line A549 was pur-
chased from the American Type Culture Collection (VR-
15™). The cells were propagated in Roswell Park Memorial
Institute 1640 (RPMI 1640) media (Gibco, USA) supple-
mented with 10 % fetal bovine serum (FBS; Hyclone,USA),
1 % penicillin/streptomycin (Solarbio, China) and main-
tained at 37 °C in a humidified atmosphere of 95 % air:
5 % CO2. Cells were subcultured every 3–4 days when
70–80 % confluence was reached. For all experiments,
A549 cells were seeded (5,000 cells/cm2) into six-well
plates for total RNA isolation, into ninety-six-well plates
for ELISA experiments, or into 60-mm dishes for protein
extraction. Experiments were repeated at three independ-
ent times and performed in triplicate each time. Experi-
ments were performed when a monolayer of A549 cells
achieved 70–80 % confluence and cells were serum-
deprived for 24 h before the drug treatments.
Cell treatment and sample collection
The drug treatments consisted of 4 parts as follow: A.
A549 cells were treated with TGF-β1 (Peprotech, USA) at
10 ng/mL, BMP-2 at 100 ng/mL, BMP-4 at 100 ng/mL
and BMP-7 at 100 ng/mL respectively, bovine serum albu-
min (BSA) was used as a control. B. A549 cells were
treated with SB203580 (Cell Signaling Technology, USA)
and/or TGF-β1. The cells were pretreated with 10 μM
SB203580 for 60 min before 10 ng/mL TGF-β1 stimula-
tion while 0.1 % DMSO used was as vehicle control. C.
A549 cells were treated with S2871 (Selleckchem, USA,
USA) and/or TGF-β1. The cells were pretreated with
10 μM S2871 for 60 min before 10 ng/mL TGF-β1 stimu-
lation while 0.1 % DMSO was used as vehicle control. D.
A549 cells were treated with S2505 (Selleckchem, USA)
and/or TGF-β1. The cells were pretreated with
10 μM S2505 for 60 min before 10 ng/mL TGF-β1 stimu-
lation while 0.1 % DMSO was used as vehicle control.
The culture supernatants were harvested 12 h after drug
treatment for ELISA measurements of ET-1. After incu-
bated with agonists or antagonists for 2 h, total RNA was
isolated from the cells by TRIzol Reagent (Invitrogen,
USA) according to the manufacturer’s instructions. RNA
integrity was checked electrophoretically and purity was
quantified by using spectrophotometry. Cell lysate were
collected with cell lysis buffer (P0013, Beyotime Biotech-
nology, China) with 1 μM phenylmethanesulfonyl fluoride
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(PMSF) at 0, 5, 10, 15 and 30 min after drug treatment re-
spectively according to the experimental conditions for
western blotting. Total protein concentration was mea-
sured via a spectrophotometer using the bicinchoninic
acid (BCA) protein assay kit (P0010S, Beyotime Biotech-
nology, China) with BSA utilised as the protein standard.
For immunofluorescence analysis by CLSM, the cells were
fixed in 4 % paraformaldehyde for 30 min after TGF-β1
treatment for 15, 30 and 60 min respectively.
Real-time PCR
After incubations with agonists or antagonists for 2 h, total
RNA was isolated from the cells by TRIzol Reagent and re-
verse transcription was performed on 1 μg RNA with oligo
(dT) primers in 20 μL reactions by using the Prime-
ScriptTM RT reagent kit with gDNA Eraser (Perfect Real
Time) (TAKARA BIO INC, RR047A, Japan) according to
the manufacturer’s instructions. Gene expression of ET-1,
PPAR-γ and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was evaluated using real-time PCR and SYBR
Green I dye (Bio-Rad, Hercules, CA). The primers of ET-1,
PPAR-γ and GAPDH were obtained from Invitrogen
(Life Technologies, Shanghai). The sequence of primers
for the amplification of ET-1, PPAR-γ and GAPDH
were as follows: ET-1 (human) forward: 5-CCAAT
CTTGGAACAGTCTTTTCCT-3, reverse: 5-GGACA
TCATTTGGGTCAACACTCC-3; PPAR-γ (human)
forward: 5-ACTCCCTCATGGCAATTGAATGTC-3,
reverse: 5-ATACTCTGTGATCTCCTGCACAGCC-3;
GAPDH (human) forward: 5-GAAGGTGAAGGTCG
GAGT-3, reverse: 5-GAAGATGGTGATGGGATTC-3.
After 15 min of initial activation at 95 °C, PCR was
carried out for 40 cycles at 94 °C for 15 s and 56.5 °C
(ET-1) or 58.0 °C (PPAR-γ) for 30s. GAPDH was per-
formed simultaneously and used as the housekeeping
gene. The threshold cycle (Ct) value was measured, and
the comparative gene expression was calculated by 2−△△Ct
method as described previously [30].
ET-1 ELISA
Confluent cells were incubated with serum-free
RM1640 for 24 h prior to drug treatment. TGF-β1,
SB203580, S2871 and S2505 were added into the
culture supernatant for 12 h and the supernatant was
harvested and stored at − 80 °C. For the SB203580 +
TGF-β1, S2871 + TGF-β1 and S2505 + TGF-β1 groups,
SB203580, S2871 and S2505 were added into the super-
natant respectively for 60 min then incubated with
TGF-β1 for 12 h. All assays were performed in
triplicates and the ET-1 protein concentration in the
supernatants was measured using human endothelin-
1QuantiGlo ELISA kit (R&D Systems, USA) according
to the manufacturer’s instructions.
Western Blotting
20 μg of total protein from each sample was separated
by 10 % SDS polyacrylamide gels (SDS-PAGE). After
electrophoresis, separated proteins were transferred
onto the polyvinylidene fluoride (PVDF) membranes
(Millipore, Billerica, MA, USA) and the membranes
were blocked for 2 h at room temperature with 5 %
BSA in TBST. Membranes were then probed with pri-
mary antibodies (1:10,000 for β-actin and 1:1000 for
other antibodies) at 4 °C overnight. The antibodies used
were phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP®
Rabbit mAb (4511, Cell Signaling Technology), p38
MAPK (D13E1) XP® Rabbit mAb (8690, Cell Signaling
Technology), phospho-Smad2 (Ser465/467) (138D4)
rabbit mAb (3108, Cell Signaling Technology), Smad2
(D43B4) XP® Rabbit mAb (5339, Cell Signaling Tech-
nology), phospho-SAPK/JNK (Thr183/Tyr185) (81E11)
rabbit mAb (4668, Cell Signaling Technology),
phospho-NF-kB p65 (Ser536) (93H1) rabbit mAb
(3033, Cell Signaling Technology), NF-kB p65 (C22B4)
rabbit mAb (4764, Cell Signaling Technology) and
beta-actin rabbit polyclonal antibody (#4967, Cell
Signaling Technology). After washing with TBST, mem-
branes were probed with secondary antibodies (anti-
rabbit IgG, HRP-linked antibody, #7074, Cell Signaling
Technology) for 2 h at room temperature. Immuno-
blots were visualised by enhanced chemiluminescence
and the image of western blots was scanned by Quan-
tity One software. Band densities were quantified with
freeware image analysis software, NIH Image (National
Institute of Health, Bethesda MD, USA). The results of
phosphorylated protein were normalized against the in-
tensity of the total protein in each sample. In some
western blots beta-actin was used as a protein loading
control.
Plasmid transfection
A549 cells were allowed to grow till about 80 % con-
fluency and then transfected with PPAR-γ positive or
negative plasmid. The glycerol bacterial samples con-
taining plasmids of human PPAR gamma sequence or
small interfering RNA (siRNA) were synthesized by
Invitrogen (Life Technologies, Shanghai). The glycerol
bacterial samples were amplified in Luria-Bertani (LB)
medium with 0.5 % amikacin at 37 °C overnight and
the plasmid DNA extraction was performed using
endofree maxi plasmid kit (TIANGEN BIOTECH,
Beijing). The plasmid DNA was quantified by using
spectrophotometry. Transfection was performed using
LipofectamineTM 2000 reagent (Invitrogen) following
the manufacturer’s instruction. Cells were incubated at
37 °C for 24 h in a humidified incubator containing
95 % air: 5 % CO2 and then treated with 10 ng/mL
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TGF-β1. Detailed methods are provided in the online
supplementary data.
Immunofluorescence analysis by confocal laser scanning
microscopy (CLSM)
A549 cells were serum-deprived for 24 h before treat-
ment after reaching 70–80 % confluence. TGF-β1 was
added into the cultures at 10 ng/mL for 15, 30 and
60 min respectively. After treatment the culture super-
natant was removed and the cells were washed with
PBS 3 times and then fixed in 4 % paraformaldehyde
for 30 min at room temperature, permeabilized by
0.1 % Triton X-100 in PBS for 20 min, blocked with
5 % BSA for 30 min. The cells were incubated with pri-
mary antibody of phospho-Smad2 rabbit mAb (3108,
Cell Signaling Technology) at 4 °C overnight. After PBS
washing for 3 times, secondary antibody (Alexa Fluor
488-labeled goat anti-rabbit IgG, Beyotime Inc.) was
added to the cells and incubated in the dark at room
temperature for 1 h. The cells were washed with PBS
for 3 times and mounted with propidium iodide (PI)-
containing mounting media (ZSGB-BIO, Beijing,
China) for 5 min. After washing with PBS 3 times, the
cells were observed and photographed by a confocal
laser scanning microscope.
Statistical analysis
Data are presented as means ± standard deviation of
multiple determinations. Statistical analysis was per-
formed using SPSS for windows (version 16.0,
Chicago, USA). Differences between multiple groups
were compared using One-way repeated measures
ANOVA. The difference between a control and a
treatment group or between two treatment groups was
compared by two-sample Student’s t-test where stated
in the figure legends. The difference was considered
statistically significant at P < 0.05.
Results
TGF-β1 can promote A549 cells synthesis and secretion of
ET-1
Confluent A549 cells were incubated with 10 ng/mL
TGF-β1, 100 ng/mL BMP-2, 100 ng/mL BMP-4 and
100 ng/mL BMP-7 respectively. After incubation for 2 h,
the total RNA was extracted to perform real-time qPCR
and after 12 h incubation the supernatants were har-
vested to evaluate ET-1 concentrations by ELISA. The
results of real-time qPCR demonstrated that 10 ng/mL
TGF-β1, 100 ng/mL BMP-2 and 100 ng/mL BMP-7 in-
creased the relative ET-1 mRNA levels respectively in
A549 cells but only the TGF-β1 treatment significantly
increased the levels of ET-1 protein expression when
measured by ELISA (Fig. 1).
SB203580 suppressed the activation of MAPK P38 signal
pathway and the expression of ET-1
Confluent A549 cells were treated with 10 ng/mL TGF-
β1 or 10 μM SB203580 (a p38 MAPK inhibitor) respect-
ively while cells were pre-treated with 10 μM SB203580
for 60 min before 10 ng/mL TGF-β1 stimulation for the
TGF-β1 + SB203580 group. The samples were then ana-
lyzed by real-time qPCR, ELISA and western blotting.
The results of real-time qPCR and ELISA demonstrated
that TGF-β1 increased the expression of ET-1 mRNA
and protein. SB203580 can effectively block the TGF-β1
mediated ET-1 mRNA and protein increase. The results
of western blotting demonstrated that TGF-β1 led to in-
creased protein phosphorylation of NF-kB p65, JNK/
SAPK and p38; SB203580 can effectively inhibit the ex-
pression of phospho-p38 mediated by TGF-β1 (Fig. 2).
TGF-β1 mediated Smad2 phosphorylation and nuclear
transfer
Confluent A549 cells were treated with 10 ng/mL TGF-
β1 and total protein was extracts at 0, 5, 10, 15 and
Fig. 1 Effect of TGF-β1 on ET-1 in A549 cells. Confluent A549 cells were incubated with 10 ng/mL TGF-β1, 100 ng/mL BMP-2, 100 ng/mL BMP-4
and 100 ng/mL BMP-7 respectively. The incubation times were 2 h for real-time qPCR and 12 h for ELISA. The ET-1 mRNA expression is shown in
Fig. 1a. The relative ET-1 mRNA levels (normalized to GAPDH mRNA) in TGF-β1, BMP-2 and BMP-7 group were increased than those in control
group (*p < 0.05). The results of ELISA assay in Fig. 1b demonstrated that only the TGF-β1 treatment significantly increased the levels of ET-1
protein expression (*p < 0.05). The results are presented as means ± SD of 3 independent experiments performed in triplicate. (C, control group;
TGF, TGF-β1 group; BMP-2, BMP-2 group; BMP-4, BMP-4 group; BMP-7, BMP-7 group)
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30 min respectively for western blot analysis. For im-
munofluorescence analysis by CLSM, the cells were pre-
treated without or with 10 μM SB203580 and then incu-
bated with 10 ng/mL TGF-β1 for 15, 30 and 60 min re-
spectively and nuclear transfer was observed by CLSM.
The cell nuclei stained by PI were red in color and
phosphor-Smad2 appeared green. The results of western
blot suggested that TGF-β1 increased the phosphoryl-
ation expression of Smad2. The pictures of CLSM dem-
onstrated that TGF-β1 mediated Smad2 nuclear transfer
and this process was suppressed by SB203580 (Fig. 3).
Inhibition of PPAR-γ can suppress the expression of
PPAR-γ mRNA and increase the expression of ET-1 mRNA
and protein mediated by TGF-β1, increase the expression
of P-P38 and P-Smad2
A549 cells were treated by the PPAR-γ inhibitor
(10 μM S2871) with or without 10 ng/mL TGF-β1 and
the samples were analyzed by real-time qPCR, ELISA
and western blotting. The results demonstrated that
S2871 suppressed the expression of PPAR-γ mRNA and
increased the expression of ET-1 mRNA, enhanced the
expression of ET-1 mRNA and protein mediated by
TGF-β1 and increased the expression of phospho-P38
and phospho-Smad2 (Fig. 4).
PPAR-γ silencing enhanced the expression of ET-1 mRNA
and protein mediated by TGF-β1, increase the expression
of phospho-P38 and phospho-Smad2
A549 cells were allowed to grow and attain about 80 %
confluency and the transfection with PPAR-γ siRNA
plasmid or control vectors (negative control) was per-
formed using LipofectamineTM 2000 reagent. Cells were
incubated at 37 °C for 24 h in an incubator containing
95 % air: 5 % CO2 and full humidity and then treated
with 10 ng/mL TGF-β1. The samples were collected and
analyzed by real-time qPCR, ELISA and western blotting
as described in the materials and methods. The results
of RT qPCR and ELISA showed that PPAR-γ silencing
reduced the expression of PPAR-γ mRNA, slightly in-
creased the expression of protein with no statistical sig-
nificance observed, but significantly increased the
expression of ET-1 mRNA expression and protein medi-
ated by TGF-β1. PPAR-γ silencing increased the expres-
sion of phospho-P38 and phospho-Smad2 according to
western blotting analysis (Fig. 5).
Fig. 2 Effect of SB203580 on TGF-β1-induced up-regulation of ET-1 in A549 cells. Confluent A549 cells were treated with 10 ng/mL TGF-β1 or
10 μM SB203580 respectively while cells were pre-treated with 10 μM SB203580 for 60 min before 10 ng/mL TGF-β1 stimulation for SB203580 +
TGF-β1 group. The samples were analyzed by real-time qPCR, ELISA and western blotting. The results of real-time qPCR were shown in Fig. 2a.
The relative ET-1 mRNA level (normalized to GAPDH mRNA) in TGF-β1 group was significantly increased than those in control group (*p < 0.05).
The relative ET-1 mRNA level in SB203580 + TGF-β1 group was decreased compared to TGF-β1 group (#p < 0.05). The results of ELISA assay in
Fig. 2b also demonstrated the same results that TGF-β1 treatment increased the levels of ET-1 protein expression (*p < 0.05) and the combination
of SB203580 could suppressed this effects (#p < 0.05). All the results are presented as means ± SD of 3 independent experiments performed in
triplicate. Western blotting shows that TGF-β1 made the protein phosphorylation increased of NF-kB p65, JNK/SAPK (Fig. 2c) but the inhibitors of
these pathways could not suppress the ET-1 protein expression according to the results of ELISA. TGF-β1 made the protein phosphorylation
increased of p38 and SB203580 can effectively inhibit the expression of phospho-p38 (Fig. 2d). (C, control group; TGF, TGF-β1 group; SB,
SB203580 group; SB + TGF, SB203580 + TGF-β1 group)
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S2505 can increase the expression of PPAR-γ mRNA and
suppress the expression of ET-1 mRNA and protein
mediated by TGF-β1, decrease the expression of P-P38
and P-Smad2
A549 cells were incubated with PPAR-γ agonist
(10 μM S2505) in the presence or absence of
10 ng/mL TGF-β1 and the samples were analyzed
by real-time qPCR, ELISA and western blots. The
results demonstrated that the PPAR-γ agonist,
S2505, increased the expression of PPAR-γ mRNA,
reduced the expression of ET-1 mRNA and sup-
pressed the increased expression of ET-1 mRNA
and protein mediated by TGF-β1. It also inhibited
the expression of phospho-P38 and phospho-Smad2
(Fig. 6).
PPAR-γ gene over-expression suppressed the expression
of ET-1 mRNA and protein mediated by TGF-β1, increase
the expression of P-P38 and P-Smad2
A549 cells were allowed to grow till about 80 % con-
fluency and the transfection with PPAR-γ plasmid or
control vectors (negative control) was performed using
LipofectamineTM 2000 reagent. Cells were incubated at
37 °C for 24 h in an incubator containing 95 % air: 5 %
CO2 and full humidity and then treated with 10 ng/mL
TGF-β1. The samples were collected and analyzed by
real-time qPCR, ELISA and western blotting. The results
of RT qPCR and ELISA showed that PPAR-γ gene over-
expression increased the expression of PPAR-γ mRNA,
reduced the expression of ET-1 mRNA as well as the in-
creased expression of ET-1 protein mediated by TGF-β1.
Fig. 3 TGF-β1 mediated Smad2 phosphorylation and nuclear transfer. Confluent A549 cells were treated with 10 ng/mL TGF-β1 and cell lysates
were subjected to western blotting analysis. For immunofluorescence analysis by CLSM, the cells were pre-treated without or with 10 μM
SB203580 and then incubated with 10 ng/mL TGF-β1 and fixed in 4 % paraformaldehyde, treated as described in the Materials and Methods and
the cells were observed and photographed by a confocal laser scanning microscope. The red fluorescence stained for cell nucleus and green
fluorescence stained for phosphor-Smad2. Western blotting showed that TGF-β1 increased the phosphorylation expression of Smad2 (a). The
pictures of CLSM demonstrated that TGF-β1 mediated Smad2 nuclear transfer (b), this process was suppressed by SB203580 (c)
(original magnification × 400)
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PPAR-γ gene over-expression inhibited the expression of
phospho-P38 and phospho-Smad2 according to western
blots (Fig. 7).
Discussion
The pathogenesis of PAH still remains elusive, partly
because many diseases can lead to PAH and multiple
signaling pathways are implicated in this process. There
is increasing evidence that the increased expression of
ET-1 and the activation of MAPKs are linked to PAH
[10, 31]. Interaction of MAPK with TGF-β1 activated
signaling cascades were associated with PAH [15, 32].
The serum levels of TGF-β1 were significantly higher
in patients with schistosomiasis-associated PAH com-
pared with patients with schistosomiasis but without
PAH [33] and TGF-β induced ET-1 expression [34–36].
PPAR-γ is a ligand-activated nuclear receptor and early
research suggested that PPAR-γ activators suppressed the
ET-1 production both in vitro and in vivo [27, 29, 37].
The way in which TGF-β1 and PPAR-γ regulate the ex-
pression of ET-1 and what signaling pathways participate
in this process remains unclear. The aim of our study was
to investigate the interactions between PPAR-γ, TGF-β1
and ET-1 and the underlying biochemical mechanisms
whereby this occurs in A549 cells.
We demonstrated that TGF-β1 could significantly pro-
mote the expression of ET-1 mRNA and protein in
A549 cells, increase the phosphorylation status of P38
MAPK and Smad2. SB203580 pre-treated A549 cells, re-
sulted in the inhibition of p38 MAPK transduction and
nuclear transfer of Smad2 respectively and a suppressive
effect on the TGF-β1-induced production of ET-1. These
results suggest that both p38 MAPK and Smad2 are in-
volved in TGF-β1 mediated release of ET-1 by A549
cells. These results are consistent with previous studies
suggesting that TGF-β1 strongly stimulated the synthesis
and secretion of ET-1 in endothelial cells [36, 38], pan-
creatic stellate cells [35] and lung fibroblasts [34]. TGF-
β signaling should be a complex phenomenon and
several studies with cell and animal models have reported
that TGF-β induced ET-1 expression is mediated through
the ALK5/Smad3 and p38 MAPK pathways [36, 39].
TGF-β increased Smad2 and Smad3 phosphorylation and
promoted Smad hetero-complex formation and nuclear
Fig. 4 Inhibition of PPAR-γ on the expression of PPAR-γ and ET-1 mRNA. A549 cells were incubated with 10 ng/mL TGF-β1 or 10 μM S2871
respectively while cells were pre-treated with 10 μM S2871 for 60 min before 10 ng/mL TGF-β1 stimulation for S2871 + TGF-β1 group. Then the
samples were collected and analyzed by real-time qPCR, ELISA and western blotting as described previously. The relative PPAR-γ mRNA level
(normalized to GAPDH mRNA) in S2871 group was significantly decreased (a) while compared to control group and the ET-1 level was significantly
increased (b) (*p < 0.05). The increased expression of ET-1 mRNA (c) and protein (d) mediated by TGF-β1was enhanced by S2871 (*p < 0.05). Western
blotting showed that S2871 increased the expression of phospho-P38 and phospho-Smad2 (e). The results are presented as means ± SD of 3
independent experiments performed in triplicate. (C, control group; S, S2871 group; TGF, TGF-β1 group; S + TGF, S2871 + TGF-β1 group)
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accumulation in myofibroblasts [40]. Our results demon-
strate that TGF-β1, 100 ng/mL BMP-2 and 100 ng/mL
BMP-7 increased the relative ET-1 mRNA levels respect-
ively in A549 cells but only the TGF-β1 treatment signifi-
cantly increased the levels of ET-1 protein expression.
There may be several reasons as to why BMP-2 and BMP-
7 could not significantly increase the expression of ET-1
protein as well as ET-1 mRNA. The process from ET-1
mRNA to protein expression included translation, post-
translational processing and secretion to certain tissues,
and multiple factors participate in this process. Any alter-
ations in the various steps in this process would lead to
the inconsistencies between mRNA and protein levels
while the result of protein expression is probably more re-
liable index. We investigated the possible pathways by
western blot analysis and the results showed that TGF-β1
allowed increases in protein phosphorylation of NF-kB
p65, JNK/SAPK but the inhibitors of these pathways could
Fig. 5 Silencing of PPAR-γ silence on the expression of ET-1. A549 cells were transfected with PPAR-γ siRNA plasmid or control vectors (negative
control) using LipofectamineTM 2000 reagent and incubated at 37 °C for 24 h in an incubator containing 95 % air: 5 % CO2 and full humidity. Then
transfected cells were treated with 10 ng/mL TGF-β1and the samples were collected and analyzed by real-time qPCR, ELISA and western blotting.
The results of electrophoresis and real-time qPCR showed that PPAR-γ silencing reduced the expression of PPAR-γ mRNA (a, b) (*p < 0.05 while
compared to NC). The results of RT qPCR (c) and ELISA (d) showed that PPAR-γ silencing slightly decreased the expression of ET-1 mRNA expression
(p = 0.5206 while compared to NC) and increased the expression of ET-1 protein with no statistical significance (p = 0.0902 while compared to NC). The
increased ET-1 mRNA level (c) and protein concentration (d) mediated by TGF-β1 was enhanced by transfection of PPAR-γ siRNA plasmid with
statistical significance (*p < 0.05 while PPARsiRNA + TGF group compared to TGF group). Western blotting showed that PPAR-γ silencing increased the
expression of phospho-p38 and phospho-Smad2 (e). The results are presented as means ± SD of 3 independent experiments. (NC, negative control
group; PPARsiRNA, PPAR-γ silencing group; TGF, TGF-β1 group; PPARsiRNA + TGF, PPAR-γ silencing + TGF-β1 group)
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not suppress the ET-1 protein expression when the results
of ELISA were considered. It was also found that TGF-β1
allowed increases in protein phosphorylation of p38
MAPK and Smad2 and that SB203580 can effectively in-
hibit the expression of phspho-p38 MAPK and the nu-
clear transfer Smad2. Therefore our results strongly
suggest that both p38 MAPK and Smad2 were involved in
the release of ET-1 mediated by TGF-β1.
Moreover, we have demonstrated that transfecting
cells with PPAR-γ siRNA plasmid or pre-treating cells
with S2871 increased the expression of phospho-p38
MAPK and phospho-Smad2 and enhanced the expres-
sion of ET-1 mRNA and protein mediated by TGF-β1.
However, transfecting cells with PPAR-γ plasmid or pre-
treating cells with S2505 decreased the expression of
phospho-P38 MAPK and phospho-Smad2 and
suppressed the expression of ET-1 mRNA and protein
mediated by TGF-β1. These results suggest the TGF-
induced ET-1 release was dependent on PPAR-γ. Others
have shown that PPAR-γ agonist rosiglitazone attenuated
ET-1-induced pulmonary vasoconstriction in Sprague-
Dawley rats [37, 41–43] and inhibited the activation of
p38 MAPK in murine macrophages [44]. Rosiglitazone
increased expression of PPAR-γ mRNA and also sup-
pressed the expression of ET-1 mRNA in animal models
[28, 45]. When human pulmonary artery endothelial
cells were transfected with PPAR-γ siRNA and this was
shown to reduce PPAR-γ protein and increased ET-1
protein [46].
In this study, we showed that TGF-β1 promoted the
synthesis and secretion of ET-1 in A549 cells, increased
the expression of phospho-p38 MAPK and phospho-
Smad2 and induced an increase in nuclear transfer of
Smad2. SB203580 suppressed the activation of MAPK
P38 signal pathway, nuclear transfer of Smad2 and the
expression of ET-1. Inhibition of PPAR-γ or PPAR-γ
gene silencing suppressed the expression of PPAR-γ
mRNA and increased the expression of ET-1 mRNA and
protein mediated by TGF-β1 and also increased the ex-
pression of phospho-P38 MAPK and phospho-Smad2.
However, activation of PPAR-γ or PPAR-γ gene over-
expression suppressed the expression of ET-1 mRNA
and protein mediated by TGF-β1 and increased the ex-
pression of phospho-p38 and phospho-Smad2. These
Fig. 6 Effect of S2505 on the expression of PPAR-γ and ET-1 mRNA. A549 cells were incubated with 10 ng/mL TGF-β1 or 10 μM S2505 respectively
while cells were pre-treated with 10 μM S2505 for 60 min before 10 ng/mL TGF-β1 stimulation for the S2505 + TGF-β1 group. Then the samples were
collected and analyzed by real-time qPCR, ELISA and western blotting. The relative PPAR-γ mRNA level (normalized to GAPDH mRNA) in S2505 group
was significantly increased (a) while compared to control group and the ET-1 level was significantly decreased (b) (*p < 0.05). The increased expression
of ET-1 mRNA (c) and protein (d) mediated by TGF-β1was suppressed by S2505 (#p < 0.05). Western blotting showed that S2505 decreased
the expression of phospho-P38 and phospho-Smad2 (e). The results are presented as means ± SD of 3 independent experiments performed in
triplicate. (C, control group; S2505, S2505 group; TGF, TGF-β1 group; S2505 + TGF, S2505 + TGF-β1 group)
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results suggest that the release of TGF-induced ET-1
depended on PPAR-γ through the p38 MAPK and
Smad2 pathways. PPAR-γ could, therefore, be considered
as a potential therapeutic target for PAH. However, in
the present study, we investigated only the interaction
between PPAR-γ, TGF-β1 and ET-1 in vitro. Therefore,
there is a need to further study the relationship between
PPAR-γ, TGF-β1 and ET-1 in vivo and to investigate the
anti- vasoconstriction effect of PPAR-γ and its potential
role in PAH treatment.
Conclusions
In conclusion, this study shows that TGF-β1-induced
production of ET-1, increased phosphorylation of p38
MAPK and Smad2 nuclear transfer could be pre-
vented by using SB20308 and regulated by PPAR-γ,
suggested that p38 MAPK and Smad2 signaling
transduction is involved in TGF-β1 induced ET-1
release and that this process was PPAR-γ dependent
in A549 cells.
Abbreviations
CLSM, confocal laser scanning microscopy; ECM, extracellular matrix; ELISA,
enzyme-linked immunosorbent assay; ET-1, endothelin-1; mAb, monoclonal
antibody; PAH, pulmonary arterial hypertension; PASMC, pulmonary arterial
smooth muscle cell; PPAR-γ, peroxisome proliferator-activated receptor
gamma; PVR, pulmonary vascular resistance; TGF-β1, transforming growth
factor beta 1
Acknowledgements
This study was supported by grants from the National Natural Science
Foundation of China, Nos. 81160013, 81060007 and 81560321, Science and
Technique Research Projects of Guangxi, No.1140003B-93 and the Key
Programs of Natural Science Foundation of Guangxi, No.2011GXNSFD018039.
Authors’ contributions
S.X., Y.Z., Y.Q, X.H., Y.J., and W.L., were involved with acquisition, analysis, or
interpretation of the data. L.P., B.X. and S.R.S. contributed to the design and
the conception of the study and interpretation of the data. All authors were
involved with drafting/revising and approving the manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1The First Clinical Medical College of Jinan University, Guangzhou 510630,
Guangdong Province, China. 2Department of Intensive Care Unit, the
People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021,
China. 3Department of Central Laboratory, Youjiang Medical University for
Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China.
4Department of Digestive Medicine, Youjiang Medical University for
Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China.
5Department of Respiratory Medicine, Youjiang Medical University for
Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China.
6Department of Surgery and Cancer, Imperial College London, Chelsea and
Westminster Hospital, London SW10 9NH, UK. 7Department of Intensive Care
Medicine, Youjiang Medical University for Nationalities, Baise 533000,
Guangxi Zhuang Autonomous Region, China.
Received: 16 May 2016 Accepted: 7 June 2016
References
1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med.
2004;351:1655–65.
Fig. 7 PPAR-γ gene over-expression suppresses the expression of ET-1 mRNA and protein. A549 cells were transfected with PPAR-γ plasmid or
control vectors (negative control) using LipofectamineTM 2000 reagent and incubated at 37 °C for 24 h in an incubator containing 95 % air, 5 %
CO2 and full humidity. The cells were then treated with 10 ng/mL TGF-β1 and the samples were analyzed by real-time qPCR, ELISA and western
blotting. The results of real-time qPCR showed that the relative PPAR-γ mRNA level (normalized to GAPDH mRNA) in PPAR-γ transfection group
was significantly increased than those in control group (a) and ET-1 mRNA level was significantly decreased (b) (*p < 0.05). The increased ET-1
mRNA level (b) and protein concentration (c) mediated by TGF-β1 was suppressed by transfection of PPAR-γ plasmid. Western blotting showed
that PPAR-γ gene over-expression decreased the expression of phospho-P38 and phospho-Smad2 (d). The results are presented as means ± SD of
3 independent experiments. (NC, negative control group; PPARγ, PPAR-γ plasmid transfection group; TGF, TGF-β1 group; PPARγ + TGF, PPAR-γ
plasmid transfection + TGF-β1 group)
Xiang et al. Journal of Inflammation  (2016) 13:19 Page 10 of 11
2. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM,
Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients
with primary pulmonary hypertension. Results from a national prospective
registry. Ann Intern Med. 1991;115:343–9.
3. Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu
B, Hu SS, et al. Registry and survival study in chinese patients with
idiopathic and familial pulmonary arterial hypertension. Chest.
2007;132:373–9.
4. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry
for pulmonary arterial hypertension: 1982–2006. Eur Respir J. 2007;30:1103–10.
5. Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL. Compelling evidence
of long-term outcomes in pulmonary arterial hypertension? A clinical
perspective. J Am Coll Cardiol. 2011;57:1053–61.
6. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD.
Integration of clinical and hemodynamic parameters in the prediction of
long-term survival in patients with pulmonary arterial hypertension. Chest.
2011;139:1285–93.
7. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352:719–25.
8. Malenfant S, Neyron AS, Paulin R, Potus F, Meloche J, Provencher S, Bonnet
S. Signal transduction in the development of pulmonary arterial
hypertension. Pulm Circ. 2013;3:278–93.
9. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F,
Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation,
growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol.
2009;54:S10–19.
10. Crosswhite P, Sun Z. Molecular mechanisms of pulmonary arterial
remodeling. Mol Med. 2014;20:191–201.
11. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial
hypertension. Cardiovasc Res. 2004;61:227–37.
12. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling
pathways in vascular smooth muscle cells. Curr Vasc Pharmacol. 2007;5:45–52.
13. Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial
hypertension. Glob Cardiol Sci Pract. 2014;2014:62–78.
14. Bressollette E, Dupuis J, Bonan R, Doucet S, Cernacek P, Tardif JC.
Intravascular ultrasound assessment of pulmonary vascular disease in
patients with pulmonary hypertension. Chest. 2001;120:809–15.
15. Budd DC, Holmes AM. Targeting TGFbeta superfamily ligand accessory
proteins as novel therapeutics for chronic lung disorders. Pharmacol Ther.
2012;135:279–91.
16. Lambers C, Roth M, Zhong J, Campregher C, Binder P, Burian B, Petkov V,
Block LH. The interaction of endothelin-1 and TGF-beta1 mediates vascular
cell remodeling. PLoS One. 2013;8:e73399.
17. Singh I, Ma KC, Berlin DA. Pathophysiology of pulmonary hypertension in
chronic parenchymal lung disease. Am J Med. 2016;129:366–71.
18. Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco
T, Galie N, Ghio S, Gibbs S, et al. Pulmonary hypertension in chronic lung
diseases. J Am Coll Cardiol. 2013;62:D109–116.
19. Weijun T, Zhenshun C, Qiuyue T, Ting W, Min L, Li Z. Transforming growth
factor-beta1 induces epithelial-mesenchymal transition in A549 cells by up-
regulating expression of calpain. Zhonghua Jie He He Hu Xi Za Zhi.
2015;38:202–5.
20. Kim JH, Jang YS, Eom KS, Hwang YI, Kang HR, Jang SH, Kim CH, Park YB, Lee
MG, Hyun IG, et al. Transforming growth factor beta1 induces epithelial-to-
mesenchymal transition of A549 cells. J Korean Med Sci. 2007;22:898–904.
21. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces
human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res.
2005;6:56.
22. Ramos C, Becerril C, Montano M, Garcia-De-Alba C, Ramirez R, Checa M,
Pardo A, Selman M. FGF-1 reverts epithelial-mesenchymal transition induced
by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell
Mol Physiol. 2010;299:L222–231.
23. Luo YH, Ouyang PB, Tian J, Guo XJ, Duan XC. Rosiglitazone inhibits
TGF-beta 1 induced activation of human Tenon fibroblasts via p38 signal
pathway. PLoS One. 2014;9:e105796.
24. Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on
TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial
cells. Respir Res. 2010;11:21.
25. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of
PPARgamma. Annu Rev Biochem. 2008;77:289–312.
26. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the
cardiovascular system. Antioxid Redox Signal. 2009;11:1415–52.
27. Martin-Nizard F, Furman C, Delerive P, Kandoussi A, Fruchart JC, Staels B,
Duriez P. Peroxisome proliferator-activated receptor activators inhibit
oxidized low-density lipoprotein-induced endothelin-1 secretion in
endothelial cells. J Cardiovasc Pharmacol. 2002;40:822–31.
28. Kim EK, Lee JH, Oh YM, Lee YS, Lee SD. Rosiglitazone attenuates
hypoxia-induced pulmonary arterial hypertension in rats. Respirology.
2010;15:659–68.
29. Kang BY, Kleinhenz JM, Murphy TC, Hart CM. The PPARgamma ligand
rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and
in vivo. Am J Physiol Lung Cell Mol Physiol. 2011;301:L881–891.
30. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative
C(T) method. Nat Protoc. 2008;3:1101–8.
31. Talati M, West J, Blackwell TR, Loyd JE, Meyrick B. BMPR2 mutation alters the
lung macrophage endothelin-1 cascade in a mouse model and patients
with heritable pulmonary artery hypertension. Am J Physiol Lung Cell Mol
Physiol. 2010;299:L363–373.
32. West J. Cross talk between Smad, MAPK, and actin in the etiology of
pulmonary arterial hypertension. Adv Exp Med Biol. 2010;661:265–78.
33. Ferreira Rde C, Montenegro SM, Domingues AL, Bandeira AP, Silveira CA,
Leite LA, et al. TGF beta and IL13 in schistosomiasis mansoni associated
pulmonary arterial hypertension; a descriptive study with comparative
groups. BMC Infect Dis. 2014;14:282.
34. Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ,
Horowitz JC. Endothelin-1 and transforming growth factor-beta1
independently induce fibroblast resistance to apoptosis via AKT activation.
Am J Respir Cell Mol Biol. 2009;41:484–93.
35. Jonitz A, Fitzner B, Jaster R. Molecular determinants of the profibrogenic
effects of endothelin-1 in pancreatic stellate cells. World J Gastroenterol.
2009;15:4143–9.
36. Castanares C, Redondo-Horcajo M, Magan-Marchal N, ten Dijke P, Lamas S,
Rodriguez-Pascual F. Signaling by ALK5 mediates TGF-beta-induced ET-1
expression in endothelial cells: a role for migration and proliferation. J Cell
Sci. 2007;120:1256–66.
37. Liu Y, Tian XY, Huang Y, Wang N. Rosiglitazone attenuated endothelin-1-
induced vasoconstriction of pulmonary arteries in the Rat model of
pulmonary arterial hypertension via differential regulation of ET-1 receptors.
PPAR Res. 2014;2014:374075.
38. Star GP, Giovinazzo M, Langleben D. Effects of bone morphogenic proteins
and transforming growth factor-beta on in-vitro production of endothelin-1
by human pulmonary microvascular endothelial cells. Vascul Pharmacol.
2009;50:45–50.
39. Tong XK, Hamel E. Transforming growth factor-1 impairs endothelin-1-
mediated contraction of brain vessels by inducing mitogen-activated
protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase. Mol
Pharmacol. 2009;72:1476–83.
40. Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis
(scleroderma). Front Biosci (Schol Ed). 2009;1:226–35.
41. Tian J, Wong WT, Tian XY, Zhang P, Huang Y, Wang N. Rosiglitazone
attenuates endothelin-1-induced vasoconstriction by upregulating
endothelial expression of endothelin B receptor. Hypertension.
2010;56:129–35.
42. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of
peroxisome proliferator-activated receptor-alpha and -gamma activators on
vascular remodeling in endothelin-dependent hypertension. Arterioscler
Thromb Vasc Biol. 2003;23:45–51.
43. Montezano AC, Amiri F, Tostes RC, Touyz RM, Schiffrin EL. Inhibitory effects
of PPAR-gamma on endothelin-1-induced inflammatory pathways in
vascular smooth muscle cells from normotensive and hypertensive rats.
J Am Soc Hypertens. 2007;1:150–60.
44. Lin CF, Young KC, Bai CH, Yu BC, Ma CT, Chien YC, Chiang CL, Liao CS, Lai
HW, Tsao CW. Rosiglitazone regulates anti-inflammation and growth
inhibition via PTEN. Biomed Res Int. 2014;2014:787924.
45. Matsumoto T, Kobayashi T, Kamata K. Relationships among ET-1,
PPARgamma, oxidative stress and endothelial dysfunction in diabetic
animals. J Smooth Muscle Res. 2008;44:41–55.
46. Bum-Yong K, Park KK, Green DE, Bijli KM, Searles CD, Sutliff RL, Michael H.
Hypoxia mediates mutual repression between microRNA-27a and PPARγ in
the pulmonary vasculature. Plos One. 2013;8:e79503.
Xiang et al. Journal of Inflammation  (2016) 13:19 Page 11 of 11
